Table 2.

Dose-response relationship of neurotoxic action of 3NP in the rat striatum after intrastriatal administration and protection against 3NP toxicity by the NMDA antagonist CPP

Treatment, nmol	Striatal lesion volume, mm3	%	Density of neurons within lesion, NV; mean × 106/mm3 ± SEM	%	Neuronal loss, mean ± SEM	%	n
Vehicle	0.15  ± 0.02	0	0.135  ± 0.003	100	313  ± 41	0	6
3NP 100	1.95  ± 0.32	25	0.028  ± 0.008	21	217,553  ± 17,004	21	6
3NP 250	5.48  ± 0.52	71	0.023  ± 0.002	17	637,720  ± 56,849	62	6
3NP 500	7.73  ± 0.59	100	0.005  ± 0.001	4	1,024,391  ± 97,970	100	6
CPP 250 (4 h)	0.13  ± 0.03	0	0.135  ± 0.004	100	227  ± 39	0	6
3NP 250 (4 h)	5.60  ± 0.38	100	0.023  ± 0.0025	17	642,024  ± 47,203	100	11
3NP + CPP 250 (4 h)	4.01  ± 0.62*	72	0.047  ± 0.0045***	35	346,841  ± 47,148***	54	11
CPP 250 (7 d)	0.14  ± 0.02	0	0.134  ± 0.003	100	237  ± 42	0	6
3NP 250 (7 d)	5.84  ± 0.69	100	0.019  ± 0.0025	14	682,330  ± 86,547	100	5
3NP + CPP 250 (7 d)	3.46  ± 0.72*	59	0.037  ± 0.003**	28	338,137  ± 72,747*	50	5

Morphometric analyses revealed that the striatal volume in rats subjected to microinjections of vehicle, 3NP, or CPP did not significantly differ from each other. Densities of neurons in nonlesioned parts of the striatum also did not significantly differ from each other. *, P < 0.05, **, P < 0.01, ***, P < 0.001 vs. rats treated with 3NP, 250 nmol (Student's t test).